Adelina Birceanu

Adelina Birceanu


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
CLAUDIU-EDUARD NISTORCLAUDIU-EDUARD NISTOR
CLAUDIU-EDUARD NISTOR
CGCAMELIA GAVAN
CAMELIA GAVAN
ABAdelina Birceanu
Adelina Birceanu
CBCezar Betianu
Cezar Betianu
Mara CarsoteMara Carsote
Mara Carsote
Mihai-Lucian CiobicaMihai-Lucian Ciobica
Mihai-Lucian Ciobica
Primary cardiac tumours are relatively uncommon (75% are benign). Across the other 25%, representing malignant neoplasia, sarcomas account for 75–95%, and primary cardiac intimal sarcoma (PCIS) is one of the rarest findings. We aimed to present a comprehensive review and practical considerations from a multidisciplinary perspective with regard to the most recent published data in the specific domain of PCIS. We covered the issues of awareness amid daily practice clinical presentation to ultra-qualified management in order to achieve an adequate diagnosis and prompt intervention, also emphasizing the core role of MDM2 immunostaining and MDM2 genetic analysis. An additional base for practical points was provided by a novel on-point clinical vignette with MDM2-positive status. According to our methods (PubMed database search of full-length, English publications from January 2021 to March 2023), we identified three studies and 23 single case reports represented by 22 adults (male-to-female ratio of 1.2; male population with an average age of 53.75 years, range: 35–81; woman mean age of 55.5 years, range: 34–70) and a 4-year-old child. The tumour-related clinical picture was recognized in a matter of one day to ten months on first admission. These non-specific data (with a very low index of suspicion) included heart failure at least NYHA class II, mitral regurgitation and pulmonary hypertension, acute myocardial infarction, ischemic stroke, obstructive shock, and paroxysmal atrial fibrillation. Awareness might come from other complaints such as (most common) dyspnoea, palpitation, chest pressure, cough, asthenia, sudden fatigue, weakness, malaise, anorexia, weight loss, headache, hyperhidrosis, night sweats, and epigastric pain. Two individuals were initially misdiagnosed as having endocarditis. A history of prior treated non-cardiac malignancy was registered in 3/23 subjects. Distant metastasis as the first step of detection (n = 2/23; specifically, brain and intestinal) or during follow-up (n = 6/23; namely, intestinal, brain and bone, in two cases for each, and adrenal) required additional imagery tools (26% of the patients had distant metastasis). Transoesophageal echocardiography, computed tomography (CT), magnetic resonance imagery, and even 18F-FDG positronic emission tomography-CT (which shows hypermetabolic lesions in PCIS) represent the basis of multimodal tools of investigation. Tumour size varied from 3 cm to ≥9 cm (average largest diameter of 5.5 cm). The most frequent sites were the left atrium followed by the right ventricle and the right atrium. Post-operatory histological confirmation was provided in 20/23 cases and, upon tumour biopsy, in 3/23 of them. The post-surgery maximum free-disease interval was 8 years, the fatal outcome was at the earliest two weeks since initial admission. MDM2 analysis was provided in 7/23 subjects in terms of MDM2-positive status (two out of three subjects) at immunohistochemistry and MDM2 amplification (four out of five subjects) at genetic analysis. Additionally, another three studies addressed PCISs, and two of them offered specific MDM2/MDM2 assays (n = 35 patients with PCISs); among the provided data, we mention that one cohort (n = 20) identified a rate of 55% with regard to MDM2 amplification in intimal sarcomas, and this correlated with a myxoid pattern; another cohort (n = 15) showed that MDM2-positive had a better prognostic than MDM2-negative immunostaining. To summarize, MDM2 amplification and co-amplification, for example, with MDM4, CDK4, HMGA3, CCND3, PDGFRA, TERT, KIT, CCND3, and HDAC9, might improve the diagnosis of PCIS in addition to MDM2 immunostaining since 10–20% of these tumours are MDM2-negative. Further studies are necessary to highlight MDM2 applicability as a prognostic factor and as an element to be taken into account amid multi-layered management in an otherwise very aggressive malignancy.

5 January 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
ACAdrian Constantin
Adrian Constantin
FAFlorin Achim
Florin Achim
TTTudor Turcu
Tudor Turcu
ABAdelina Birceanu
Adelina Birceanu
AEAnca Evsei
Anca Evsei
DPDragos Predescu
Dragos Predescu
Background: Giant gallbladder is an uncommon condition that can result from a benign pathology and rarely presents with malignancy. Intracholecystic papillary–tubular neoplasm (ICPN) is a relatively new entity first described by V. Adsay in 2012 and included in the World Health Classification of Digestive System Tumours in 2019. Intracholecystic papillary-tubular neoplasm is a preinvasive lesion with an incidence of around 1% that may present as four histologic subtypes—biliary, gastric, intestinal, or oncocytic—of which the biliary subtype has the highest risk of associated invasive cancer. Although invasive carcinoma is present in about 50% of cases of ICPN, these patients have a significantly better prognosis than those with usual gallbladder cancer, suggesting that the entities may have distinct biological signatures. Case report: A 77-year-old female presented to the hospital with progressive swelling in the right hemiabdomen, a loss of appetite, and weight loss. MRI highlighted a giant abdominal tumor located in the right hypochondrium and right abdominal flank with liver invasion (segment V). Preoperatively, a gallbladder 25 × 17 cm in size was noted, and the patient underwent radical cholecystectomy. It was surprising to find such a giant malignant gallbladder tumor, diagnosed as invasive poorly cohesive carcinoma associated with ICPN. Discussion: A megacholecyst is a rare discovery. Although most often found in benign pathologies, giant gallbladder cancer can be considered. The neoplastic features and the loco-regional extension of the tumor must be evaluated by imaging scans. Few cases of giant benign gallbladder have been reported in the literature; however, this appeared to be the largest resectable gallbladder carcinoma reported to date according to the literature. Conclusion: The stage of gallbladder neoplasia is not correlated with the size of the gallbladder. Regardless of tumor size, the prognosis seems to be directly related to the stage, morphology, and resectability.

25 June 2018 in Archives of the Balkan Medical Union
Verified
Journal Article
Open access
ACAdelina Birceanu Corobea
Adelina Birceanu Corobea
AEAnca Evsei
Anca Evsei
CRCristian Rosianu
Cristian Rosianu
MGMircea Gheorghe
Mircea Gheorghe
ABAdelina Birceanu
Adelina Birceanu
ALAnca Lupu
Anca Lupu

12 June 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
CLAUDIU-EDUARD NISTORCLAUDIU-EDUARD NISTOR
CLAUDIU-EDUARD NISTOR
CGCAMELIA GAVAN
CAMELIA GAVAN
ABAdelina Birceanu
Adelina Birceanu
CBCezar Betianu
Cezar Betianu
Mara CarsoteMara Carsote
Mara Carsote
Mihai-Lucian CiobicaMihai-Lucian Ciobica
Mihai-Lucian Ciobica
Camelia Stanciu Gavan, Adelina Birceanu, and Cezar Betianu were not included as authors in the original publication

12 September 2018 in Archives of the Balkan Medical Union
Verified
Journal Article
Open access
ABAdelina Birceanu
Adelina Birceanu
AEAnca Evsei
Anca Evsei
CRCristian Rosianu
Cristian Rosianu
Mircea GheorgheMircea Gheorghe
Mircea Gheorghe
GBGabriela Birceanu
Gabriela Birceanu
NCNarcis Copca
Narcis Copca

15 March 2020 in Archives of the Balkan Medical Union
Verified
Journal Article
Open access
AEAnca Evsei
Anca Evsei
JAJavier F. Andreu
Javier F. Andreu
CMCarmen M. Blazquez Maña
Carmen M. Blazquez Maña
ICInmaculada M. Mendez Coca
Inmaculada M. Mendez Coca
RSRuben Carrera Sala
Ruben Carrera Sala
NCNarcis Copca
Narcis Copca